Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Advertisement

Experimental & Molecular Medicine
  • View all journals
  • Search
  • My Account Login
  • Content Explore content
  • About the journal
  • Publish with us
  • Sign up for alerts
  • RSS feed
  1. nature
  2. experimental & molecular medicine
  3. articles
  4. article
Development of two novel nontoxic mutants of Escherichia coli heat-labile enterotoxin
Download PDF
Download PDF
  • Article
  • Open access
  • Published: 01 June 1999

Development of two novel nontoxic mutants of Escherichia coli heat-labile enterotoxin

  • Eun Jeong Park1,
  • Ji Hoon Chang,
  • Jang Seong Kim,
  • Soo Il Chung &
  • …
  • Jung Sun Yum 

Experimental & Molecular Medicine volume 31, pages 101–107 (1999)Cite this article

  • 878 Accesses

  • 2 Citations

  • 3 Altmetric

  • Metrics details

Abstract

Escherichia coli heat-labile enterotoxin (LT) is composed of catalytic A and non-catalytic homo-pentameric B subunits and causes diarrheal disease in human and animals. In order to produce a nontoxic LT for vaccine and adjuvant development, two novel derivatives of LT were constructed by a site-directed mutagenesis of A subunit; Ser63 to Tyr63 in LTS63Y and Glu110, Glu112 were deleted in LT Δ 110/112. The purified mutant LTs (mLTs) showed a similar molecular structural complex as AB5 to that of wild LT. In contrast to wild-type LT, mLTs failed to induce either elongation activity, ADP-ribosyltransferase activity, cAMP synthesis in CHO cells or fluid accumulation in mouse small intestine in vivo. Mice immunized with mLTs either intragastrically or intranasally elicited high titers of LT-specific serum and mucosal antibodies comparable to those induced by wild-type LT. These results indicate that substitution of Ser63 to Tyr63 or deletion of Glu110 and Glu112 eliminate the toxicity of LT without a change of AB5 conformation, and both mutants are immunogenic to LT itself. Therefore, both mLTs may be used to develop novel anti-diarrheal vaccines against enterotoxigenic E. coli.

Similar content being viewed by others

Safety and immunogenicity in humans of enterotoxigenic Escherichia coli double mutant heat-labile toxin administered intradermally

Article Open access 01 February 2025

Enterotoxigenic Escherichia coli heat-labile toxin drives enteropathic changes in small intestinal epithelia

Article Open access 12 November 2022

Enteropathogenic infections modulate intestinal serotonin transporter (SERT) function by activating Toll-like receptor 2 (TLR-2) in Crohn’s disease

Article Open access 19 November 2021

Article PDF

Author information

Authors and Affiliations

  1. Mogam Biotechnology Research Institute, Kyonggido, Korea

    Eun Jeong Park

Authors
  1. Eun Jeong Park
    View author publications

    Search author on:PubMed Google Scholar

  2. Ji Hoon Chang
    View author publications

    Search author on:PubMed Google Scholar

  3. Jang Seong Kim
    View author publications

    Search author on:PubMed Google Scholar

  4. Soo Il Chung
    View author publications

    Search author on:PubMed Google Scholar

  5. Jung Sun Yum
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and permissions

About this article

Cite this article

Park, E., Chang, J., Kim, J. et al. Development of two novel nontoxic mutants of Escherichia coli heat-labile enterotoxin. Exp Mol Med 31, 101–107 (1999). https://doi.org/10.1038/emm.1999.17

Download citation

  • Published: 01 June 1999

  • Issue date: 01 June 1999

  • DOI: https://doi.org/10.1038/emm.1999.17

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

Keywords

  • mutant LT (mLT)
  • ADP-ribosyltransferase activity
  • cAMP
  • immunogenicity
  • secretory IgA (sIgA)
Download PDF

Advertisement

Explore content

  • Research articles
  • Reviews & Analysis
  • News & Comment
  • Current issue
  • Collections
  • Sign up for alerts
  • RSS feed

About the journal

  • Special Feature
  • Journal Information
  • About the Editors
  • About the Partner
  • Contact
  • For Advertisers
  • Press Releases
  • Open Access Fees and Funding

Publish with us

  • For Authors & Referees
  • Language editing services
  • Submit manuscript

Search

Advanced search

Quick links

  • Explore articles by subject
  • Find a job
  • Guide to authors
  • Editorial policies

Experimental & Molecular Medicine (Exp Mol Med)

ISSN 2092-6413 (online)

ISSN 1226-3613 (print)

nature.com sitemap

About Nature Portfolio

  • About us
  • Press releases
  • Press office
  • Contact us

Discover content

  • Journals A-Z
  • Articles by subject
  • protocols.io
  • Nature Index

Publishing policies

  • Nature portfolio policies
  • Open access

Author & Researcher services

  • Reprints & permissions
  • Research data
  • Language editing
  • Scientific editing
  • Nature Masterclasses
  • Research Solutions

Libraries & institutions

  • Librarian service & tools
  • Librarian portal
  • Open research
  • Recommend to library

Advertising & partnerships

  • Advertising
  • Partnerships & Services
  • Media kits
  • Branded content

Professional development

  • Nature Awards
  • Nature Careers
  • Nature Conferences

Regional websites

  • Nature Africa
  • Nature China
  • Nature India
  • Nature Japan
  • Nature Middle East
  • Privacy Policy
  • Use of cookies
  • Legal notice
  • Accessibility statement
  • Terms & Conditions
  • Your US state privacy rights
Springer Nature

© 2025 Springer Nature Limited